Sponsors (4)
The bill provides modest, multi-year funding and statutory clarifications aimed at improving transplant access and cord blood system operations, but it increases costs for taxpayers and providers, could impose new compliance burdens, and may not expand real-world support if appropriations do not follow or if eligibility language reduces access.
Patients needing bone marrow or stem cell transplants and transplant centers: the bill authorizes an additional $2,000,000 per year (FY2027–FY2031) for the C.W. Bill Young Cell Transplantation Program, improving access to transplants and giving hospitals more predictable program funding for planning and continued services.
Hospitals and patients who rely on cord blood transplants: clarified authority or updated requirements for maintaining and accessing a national cord blood inventory should improve availability of cord blood units for transplants.
Researchers, cord blood banks, and blood banks: clearer duties and definitions in statute could streamline collection, storage, and matching processes, improving operational efficiency and research use of cord blood resources.
Patients in need of cord blood transplants: if the revised statutory language narrows eligibility or access criteria, some patients may face reduced availability of suitable cord blood units.
Program beneficiaries and providers: the bill authorizes additional funding but does not guarantee appropriations—if Congress does not appropriate the authorized amounts, expected increases in support and services may not materialize.
Hospitals, cord blood banks, and HRSA: changes in statutory requirements could impose new administrative and compliance costs to meet revised obligations.
Based on analysis of 3 sections of legislative text.
Extends and raises the annual authorization for the C.W. Bill Young Cell Transplantation Program for FY2027–2031 and replaces the cord blood inventory statutory text.
Introduced March 17, 2026 by John F. Reed · Last progress March 17, 2026
Extends federal authorization and funding levels for the C.W. Bill Young Cell Transplantation Program and revises a statutory provision governing the national cord blood inventory. It preserves the current $31,009,000 annual authorization and adds a new $33,009,000 annual authorization for fiscal years 2027–2031, and it substitutes new statutory text for the cord blood inventory provision that changes program duties or authorities.